Reduced frequency & intensity of migraine attacks after single dose of psilocybin

Psilocybin – the active ingredient in psychedelic mushrooms – shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D.  In the first and only…

Collaborative and creative policies needed to maximize psychedelics’ therapeutic potential

Research supports the promise of psychedelics in treating conditions like depression and post-traumatic stress disorder, but the future regulatory landscape for these drugs remains unclear. Experts from Baylor College of Medicine, the University of Pennsylvania, American University and Harvard Law School call for creativity and collaboration at the federal and state levels in developing policies for the use and oversight of psychedelics and a commitment to developing a strong evidence base for efficacy and safety.

People respond differently to psychedelic drugs — genetics could be the reason

Psychedelic drugs have shown benefits as treatments for cluster headaches, anxiety and depression in clinical studies, but not for everyone. Now, in ACS Chemical Neuroscience, researchers report that one reason could be common genetic variations in one serotonin receptor.

Mount Sinai’s Center for Psychedelic Psychotherapy and Trauma Research Receives $5 Million Grant From The Bob & Renee Parsons Foundation

Funds will support cutting-edge MDMA-assisted therapy for PTSD

Research News Tip Sheet: Story Ideas From Johns Hopkins

During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.